Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable
Open Access
- 1 September 2005
- journal article
- clinical trial
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 19 (5_suppl), 5-14
- https://doi.org/10.1177/0269881105056513
Abstract
The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders (≤ 3 years).Patients who required a treatment change received RLAI (2-weekly gluteal injections of 25, 37.5 or 50mg, per clinical judgement), without an oral risperidone run-in phase.A total of 382 patients were included in this 6-month open-label study; 73% of patients completed the study. A total of 84% had schizophrenia with a median duration of 1.0 year since diagnosis. Previous medications were mainly atypical antipsychotics (70%) and depot neuroleptics (24%). The main reasons for treatment change were non-compliance (42%) and insufficient efficacy (31%) of previous medication. The total Positive and Negative Syndrome Scale (PANSS) and all its subscale scores improved significantly (p ≤ 0.0001), with 40% of patients showing a 20% improvement on total PANSS. Global Assessment of Functioning, quality of life, patient satisfaction and movement disorders also improved significantly. Tolerability of RLAI was generally good and no unexpected adverse events were reported.The ensured delivery of medication with RLAI resulted in significant symptom improvement in this patient population. Direct initiation of RLAI is well accepted by patients. RLAI might represent a novel option for patients in the early phases of psychosis.Keywords
This publication has 27 references indexed in Scilit:
- Schizophrenia practice guidelines: International survey and comparisonThe British Journal of Psychiatry, 2005
- Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized TrialAmerican Journal of Psychiatry, 2005
- Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapiesInternational Clinical Psychopharmacology, 2005
- Self-awareness of cognitive functioning in schizophreniaSchizophrenia Research, 2004
- Safety and Efficacy of Long-Acting Risperidone in SchizophreniaThe Journal of Clinical Psychiatry, 2004
- Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophreniaInternational Clinical Psychopharmacology, 2003
- Treatment of Schizophrenia With Long-Acting Injectable RisperidoneThe Journal of Clinical Psychiatry, 2003
- Pharmacotherapy of first-episode psychosisExpert Opinion on Pharmacotherapy, 2003
- Pharmacological Management of First-Episode Schizophrenia and Related Nonaffective PsychosesDrugs, 2003
- Early Detection and Intervention With Schizophrenia: RationaleSchizophrenia Bulletin, 1996